Table 3. Univariable and multivariable Cox regression analysis of OS with baseline NLR and PLR (n=220 patients).
| Variables | Univariable | Multivariable | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Age (≥75 vs. <75) | 0.77 (0.52–1.15) | 0.20 | 1.22 (0.78–1.91) | 0.38 | |
| Gender (male vs. female) | 1.19 (0.84–1.69) | 0.33 | 1.19 (0.80–1.77) | 0.38 | |
| ECOG PS (2/3 vs. 0/1) | 2.31 (1.62–3.30) | <0.001 | 2.19 (1.48–3.26) | <0.001 | |
| CCI (≥3 vs. <3) | 0.99 (0.68–1.44) | 0.96 | 0.76 (0.50–1.14) | 0.19 | |
| Smoking status (never vs. current/former) | 1.28 (0.71–2.33) | 0.41 | 1.22 (0.65–2.32) | 0.54 | |
| EGFR/ALK mutation vs. none | 0.49 (0.07–3.49) | 0.47 | |||
| Liver metastases (present vs. none) | 1.65 (0.93–2.94) | 0.09 | 1.86 (0.96–3.61) | 0.07 | |
| Brain metastases (present vs. none) | 1.03 (0.61–1.74) | 0.91 | 1.02 (0.57–1.84) | 0.95 | |
| Histology (squamous vs. non-squamous) | 1.58 (1.05–2.36) | 0.03 | 1.21 (0.77–1.89) | 0.41 | |
| Presenting with aNSCLC (yes vs. no) | 1.25 (0.77–2.04) | 0.37 | 0.97 (0.57–1.65) | 0.91 | |
| Baseline NLR (≥6.4 vs. <6.4) | 2.59 (1.82–3.70) | <0.001 | 2.31 (1.46–3.64) | <0.001 | |
| Baseline PLR (≥441.8 vs. <441.8) | 2.55 (1.74–3.72) | <0.001 | 2.03 (1.22–3.37) | 0.006 | |
| BMI (≥25 vs. <25 kg/m2) | 0.88 (0.61–1.26) | 0.49 | 1.26 (0.83–1.92) | 0.29 | |
| Prior lines of palliative chemo (1 vs. 0) | 1.04 (0.42–2.54) | 0.94 | |||
There are too few patients with EGFR/ALK mutations and second line pembrolizumab recipients to include in multivariable analysis. OS, overall survival; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; CCI, Charlson comorbidity index; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; aNSCLC, advanced non-small cell lung cancer; BMI, body mass index.